When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
At StockStory, we look beyond the headlines with our independent analysis to determine whether these bearish calls are justified. Keeping that in mind, here are three stocks facing legitimate challenges and some alternatives worth exploring instead.
Amtech (ASYS)
Consensus Price Target: $22 (-1.7% implied return)
Focusing on the silicon carbide and power semiconductor sectors, Amtech Systems (NASDAQ: ASYS) produces the machinery and related chemicals needed for manufacturing semiconductors.
Why Are We Wary of ASYS?
- Annual sales declines of 14.9% for the past two years show its products and services struggled to connect with the market during this cycle
- Poor expense management has led to an operating margin of -0.7% that is below the industry average
- Underwhelming -0.8% return on capital reflects management’s difficulties in finding profitable growth opportunities, and its falling returns suggest its earlier profit pools are drying up
Amtech’s stock price of $22.37 implies a valuation ratio of 4.2x trailing 12-month price-to-sales. Check out our free in-depth research report to learn more about why ASYS doesn’t pass our bar.
American Airlines (AAL)
Consensus Price Target: $15.53 (-4.1% implied return)
One of the ‘Big Four’ airlines in the US, American Airlines (NASDAQ: AAL) is a major global air carrier that serves both business and leisure travelers through its domestic and international flights.
Why Should You Dump AAL?
- Performance surrounding its revenue passenger miles has lagged its peers
- Eroding returns on capital from an already low base indicate that management’s recent investments are destroying value
- High net-debt-to-EBITDA ratio of 7× could force the company to raise capital on unfavorable terms if market conditions deteriorate
American Airlines is trading at $16.20 per share, or 7.6x forward EV-to-EBITDA. Read our free research report to see why you should think twice about including AAL in your portfolio.
Corcept (CORT)
Consensus Price Target: $88 (10.5% implied return)
Focusing on the powerful stress hormone that affects everything from metabolism to immune function, Corcept Therapeutics (NASDAQ: CORT) develops and markets medications that modulate cortisol to treat endocrine disorders, cancer, and neurological diseases.
Why Does CORT Worry Us?
- Incremental sales over the last five years were much less profitable as its earnings per share fell by 19.4% annually while its revenue grew
- Free cash flow margin shrank by 31 percentage points over the last five years, suggesting the company is consuming more capital to stay competitive
- Diminishing returns on capital suggest its earlier profit pools are drying up
At $79.63 per share, Corcept trades at 67.3x forward P/E. Dive into our free research report to see why there are better opportunities than CORT.
Stocks We Like More
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
